Overview:

The severe acute respiratory syndrome related novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world in 2020 (1). Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing the disease spread. Several CRISPR-Cas12 based SARS-CoV-2 detection assays have been developed (2,3). Comparing to conventional RT-PCR based tests that are hindered by the need for expensive lab instrumentation, Cas12 based tests are ultrasensitive, rapid and in low-cost POCT formats.

Gene Aliases:

Cpf1 (synthetic construct)

Genbank Number:

ATB19154

References:

1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89.

2. Broughton JP, et al: Rapid detection of 2019 novel coronavirus SARS-CoV-2 using a CRISPR-based DETECTR lateral flow assay. medRxiv doi: https://doi.org/10.1101/ 2020.03.06.20032334.

3. Lucia C, et al: An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12. bioRxiv. doi: https://doi.org/10.1101/ 2020.02.29.971127.